Rifampicin

Generic Name: Rifampicin

Brand Names: Isonarif, Rifadin, Rifamate, Rifater, Rofact

Drug Type: Small Molecule

Chemical Formula: C_₄₃H_₅₈N_₄O_₁₂

CAS Number: 13292-46-1

Unique Ingredient Identifier: VJT6J7R4TR

Background: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...

Indication: Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.

Associated Conditions: Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis

Associated Therapies: Antibacterial therapy

Clinical Trials

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Phase 1

Completed

Conditions: Lymphoma, Large-Cell, Anaplastic
Disease, Hodgkin
Neoplasms
Carcinomas
Lymphoma, Non-Hodgkin

Interventions: Drug: ketoconazole
Drug: brentuximab vedotin
Drug: rifampin
Drug: midazolam

First Posted Date: 2009-12-04

Last Posted Date: 2014-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 73

Registration Number: NCT01026415

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
🇺🇸
St. Francis Medical Group Oncology & Hematology Specialists, Indianapolis, Indiana, United States

and more 3 locations

Study of VX-770 and Rifampin in Healthy Male Subjects

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-770
Drug: Rifampin

First Posted Date: 2009-11-23

Last Posted Date: 2010-05-10

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT01018368

Drug-Drug Interaction Study With Rifampin

Phase 1

Completed

Conditions: Alzheimer Disease

Interventions: Drug: BMS-708163
Drug: Rifampin

First Posted Date: 2009-10-27

Last Posted Date: 2011-01-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT01002079

Locations: 🇮🇳
Local Institution, Bangalore, India

Pregnane X Receptor (PXR) Agonist Rifampicin Effects on Glucose, Lipid and Hormone Homeostasis

Phase 4

Completed

Conditions: Glucose Tolerance

Interventions: Drug: Placebo
Drug: Rifampicin

First Posted Date: 2009-09-28

Last Posted Date: 2011-02-10

Lead Sponsor: University of Oulu

Target Recruit Count: 12

Registration Number: NCT00985270

Locations: 🇫🇮
Oulu University Hospital, Oulu, Finland

Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation

Phase 1

Completed

Conditions: Drug Interactions

Interventions: Drug: Caffeine
Drug: Ketoconazole
Drug: Rosiglitazone
Drug: Fluconazole
Drug: Flurbiprofen
Drug: Rifampin
Drug: Omeprazole
Drug: Dextromethorphan
Drug: Midazolam
Drug: Rosuvastatin

First Posted Date: 2009-08-24

Last Posted Date: 2018-01-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 87

Registration Number: NCT00964106

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness

Phase 3

Completed

Conditions: Latent Tuberculosis Infection

Interventions: Drug: Isoniazid
Drug: Rifampin

First Posted Date: 2009-07-02

Last Posted Date: 2017-12-19

Lead Sponsor: McGill University

Target Recruit Count: 6031

Registration Number: NCT00931736

Locations: 🇦🇺
Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
🇬🇭
Research and Development Unit, Komfo Anokye Teaching Hospital, Kumasi, Ghana
🇬🇳
Service de Phtisiologie, Hopital National Ignace Deen, Conakry, Guinea

and more 9 locations

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Phase 1

Completed

Conditions: Opioid Dependency
HIV Infections

Interventions: Drug: Fosamprenavir/Ritonavir
Drug: Darunavir/Ritonavir
Drug: Rifabutin
Drug: Rifampin
Drug: Buprenorphine

First Posted Date: 2009-04-08

Last Posted Date: 2014-05-06

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 63

Registration Number: NCT00877591

Locations: 🇺🇸
San Francisco General Hospital, San Francisco, California, United States

Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifampicin
Drug: Isoniazid
Drug: Pyrazinamide
Drug: Kanamycin
Drug: Moxifloxacin

First Posted Date: 2009-01-01

Last Posted Date: 2019-12-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 19

Registration Number: NCT00816426

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Pusan National Unversity Hospital (PNUH), Busan, Korea, Republic of
🇰🇷
National Medical Center, Seoul, Korea, Republic of

Study of Daily Rifapentine for Pulmonary Tuberculosis

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Drug: Rifapentine 600
Drug: Rifapentine 450
Drug: Rifampin

First Posted Date: 2008-12-25

Last Posted Date: 2018-02-06

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 153

Registration Number: NCT00814671

Locations: 🇿🇦
Universiy of Cape Town Lung Institute, Cape Town, Western Cape, South Africa

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics of YM178

Interventions: Drug: mirabegron
Drug: rifampin

First Posted Date: 2008-10-21

Last Posted Date: 2013-07-03

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 24

Registration Number: NCT00776516

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy